Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurelius Omlin

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Praxis|May 28, 2025
Interdisciplinary Swiss Consensus Recommendations on Management of Advanced Prostate CancerArnoud J Templeton, Vérane Achard, Dilara Akhoundova, et al.
Swiss Medical Weekly|August 20, 2023
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancerArnoud J Templeton, Aurelius Omlin, Dominik Berthold, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
The Lancet. Oncology|July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialShahneen K Sandhu, William R Schelman, George Wilding, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
European Urology Open Science|September 23, 2024
First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)Stefanie Fischer, Silke Gillessen, Odile Stalder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Praxis|May 28, 2025
Interdisciplinary Swiss Consensus Recommendations on Management of Advanced Prostate CancerArnoud J Templeton, Vérane Achard, Dilara Akhoundova, et al.
Swiss Medical Weekly|August 20, 2023
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancerArnoud J Templeton, Aurelius Omlin, Dominik Berthold, et al.
JCO Precision Oncology|August 7, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene AlterationsMihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
The Lancet. Oncology|July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialShahneen K Sandhu, William R Schelman, George Wilding, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
European Urology Open Science|September 23, 2024
First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)Stefanie Fischer, Silke Gillessen, Odile Stalder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Pageof 10